TY  - THES
N2  - The overall goal of this project is to conduct a sub-analysis of the primary study data to identify factors related to the magnitude of change from baseline with C7 supplementation. I will analyze the data by LC-FAO disorder diagnosis and compare those supplemented with triheptanoin (C7) versus trioctanoin (C8) to determine if any LC-FAOD had a greater response with C7 supplementation compared to C8 supplementation. Age at initial presentation was recorded and will be used as an estimate of disease severity.  In the original study, all subjects were counseled to consume 20% of their estimated total energy needs daily from C7 or C8 oil for a 4-month period while following a diet low in long-chain fats. Adherence was assessed by multiple 3-day diet records and measurement of unconsumed daily oil at the end of the study. I hypothesize that participants with a more severe phenotype and those who consumed more of the prescribed C7 will have shown a greater response.
DO  - 10.6083/g445cd61z
DO  - DOI
AB  - The overall goal of this project is to conduct a sub-analysis of the primary study data to identify factors related to the magnitude of change from baseline with C7 supplementation. I will analyze the data by LC-FAO disorder diagnosis and compare those supplemented with triheptanoin (C7) versus trioctanoin (C8) to determine if any LC-FAOD had a greater response with C7 supplementation compared to C8 supplementation. Age at initial presentation was recorded and will be used as an estimate of disease severity.  In the original study, all subjects were counseled to consume 20% of their estimated total energy needs daily from C7 or C8 oil for a 4-month period while following a diet low in long-chain fats. Adherence was assessed by multiple 3-day diet records and measurement of unconsumed daily oil at the end of the study. I hypothesize that participants with a more severe phenotype and those who consumed more of the prescribed C7 will have shown a greater response.
AD  - Oregon Health and Science University
T1  - Triheptanoin supplementation in long-chain fatty acid oxidation disorder patients
DA  - 2019
AU  - Brown, Georgia
L1  - https://digitalcollections.ohsu.edu/record/7723/files/Brown.Georgia.2019.pdf
PB  - Oregon Health and Science University
LA  - eng
PY  - 2019
ID  - 7723
L4  - https://digitalcollections.ohsu.edu/record/7723/files/Brown.Georgia.2019.pdf
KW  - vlcad deficiency
KW  - cpt2 deficiency
KW  - lchad deficiency
KW  - triheptanoin
TI  - Triheptanoin supplementation in long-chain fatty acid oxidation disorder patients
Y1  - 2019
L2  - https://digitalcollections.ohsu.edu/record/7723/files/Brown.Georgia.2019.pdf
LK  - https://digitalcollections.ohsu.edu/record/7723/files/Brown.Georgia.2019.pdf
UR  - https://digitalcollections.ohsu.edu/record/7723/files/Brown.Georgia.2019.pdf
ER  -